Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts

Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only one of its questions is specific to axial symptoms. Alternatively, the Ankylosing Spondylitis Disease Activity Score (ASDAS) excludes assessment of enthesitis, gives less weight to peripheral activity and is considered […]

Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library

Plenary Presentations - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library

Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies - ACR Meeting Abstracts

Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis - touchIMMUNOLOGY

Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis

Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies - ACR Meeting Abstracts

PDF) Axial involvement in psoriatic arthritis: An update for rheumatologists

Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA - ACR Meeting Abstracts

Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials - ACR Meeting Abstracts

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement - ACR Meeting Abstracts

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies - The Lancet Rheumatology

PDF) The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

PDF) Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA